{"id":"W4311691578","doi":"10.1016/s2213-2600(22)00437-4","title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","year":2022,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; Interim analysis; Internal medicine; Progression-free survival; Lung cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Surrogate endpoint; Hazard ratio; Anaplastic lymphoma kinase; Cancer; Surgery; Phases of clinical research; Confidence interval; Randomized controlled trial; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002827164,0.0009766341,0.003287236,0.0003991431,0.0002288553,0.001334182,0.0007303677,0.001150736,0.00192196],"category_scores_gemma":[0.003275357,0.0004490855,0.003681644,0.0005194611,0.0006093584,0.001447757,0.0003244043,0.002779111,0.0003259615],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001619289,"about_ca_system_score_gemma":0.0008108504,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001346129,"about_ca_topic_score_gemma":0.004285515,"domain_scores_codex":[0.9988387,0.0005941467,0.00009099091,0.0001879826,0.0001489843,0.0001392422],"domain_scores_gemma":[0.9980565,0.0007884338,0.0006896348,0.0001118589,0.0001188776,0.0002348106],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8827665,0.001076529,0.0107522,0.002210547,0.008659333,0.00008555592,0.0001159622,0.002256786,0.004530531,0.000138974,0.002417841,0.08498931],"study_design_scores_gemma":[0.7355805,0.1073584,0.123275,0.0004320371,0.0194574,0.0007293874,0.000174191,0.003686075,0.002598198,0.0006891149,0.005835408,0.0001843044],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9537729,0.03960146,0.0004777467,0.0009662965,0.0002657836,0.000265773,0.002476723,0.0001016885,0.002071583],"genre_scores_gemma":[0.9911702,0.004758317,0.0003304593,0.0006587464,0.0001896606,0.0001146918,0.002054754,0.00002020185,0.0007029899],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003287236,"threshold_uncertainty_score":0.01495165,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06995470582299267,"score_gpt":0.3998493722953477,"score_spread":0.329894666472355,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}